-
Amitriptyline as a Dopamine Neuroprotective Therapy
… suggests that AMI has pharmacological properties distinct from other antidepressant medications that makes it more … venlafaxine, for effects on protecting dopamine nerve cells from degeneration in a toxin model of parkinsonism. No …
-
Assess p935 LRRK2 and Total LRRK2 Levels Using an MSD Assay in Whole Blood
… of the day. Study Design: We will obtain blood samples from people with and without Parkinson's disease from the 24-hour Biofluid Study and measure the amount of …
-
Optimization of Dopamine Compounds for the Treatment of L-DOPA-induced Dyskinesias (LIDs)
… This grant builds upon the research from a prior grant: Optimization of Dopamine D4 Antagonists … in order to better evaluate our lead molecules. Work from this funding period is expected to deliver a novel …
-
Evaluation of LRRK2 Kinase Activity in Blood Cells
… This grant builds upon the research from a prior grant: Kinase Activity in Lymphocytes Promising … THP-1, a popular laboratory cell line originating from leukemia (blood cancer) research. The work will be …
-
Characterization, Optimization and Validation of a Preformed Fibril Pre-clinical Model of Parkinson's Disease
… involved in Parkinson's) spread across brain regions from a single point of origin. The current study's objective … for multiple investigators to use the same platform from which to benchmark novel treatment strategies to bring …
-
The Role of Inflammation and Risk of Parkinson's Disease in People with GBA1 Mutations
… risk of PD. Study Design: We will collect blood samples from people with and without Parkinson's, some of whom carry … treating Parkinson's disease, and if so, who will benefit from such drugs the most. Next Steps for Development: If our …